President Biden’s Health Update

Hunter Biden, son of former President Joe Biden, discussed his father’s health during a recent interview with BBC Newsnight. He revealed that the prostate cancer diagnosed in 2025 has progressed further. The cancer, described by Hunter as ‘very painful’ and ‘debilitating,’ has metastasized into the bones.

In May 2025, Joe Biden announced his prostate cancer diagnosis after a routine examination identified a small nodule. His office noted that while this form of cancer is aggressive, it remains hormone-sensitive, allowing effective management. Biden underwent both hormone therapy and radiation treatment, completing the latter in October 2025 at Penn Medicine Radiation Oncology in Philadelphia.

Prostate cancer treatments include hormone therapy, chemotherapy, targeted therapy, immunotherapy, and radiopharmaceutical treatments. Fox News Digital sought comments from Biden’s office regarding his current status.

Understanding Prostate Cancer

Prostate cancer develops in the prostate gland. Its incidence has been rising by approximately 3% annually from 2014 to 2021, as per the American Cancer Society (ACS). Notably, advanced-stage cases increased by about 5% annually within the same timeframe.

The ACS predicts 333,830 new diagnoses and 36,320 deaths from prostate cancer in the U.S. for 2026. One in eight men will face this diagnosis in their lifetime, with a majority of cases affecting those 65 and older. Typically, diagnosis occurs at age 67, with younger men rarely affected.

Symptoms and Screening for Prostate Cancer

Early detection through routine screening often catches the disease before symptoms appear. Initial signs might include urinary issues, like a weak or slow stream, urgency, or blood in urine or bodily fluids. Advanced symptoms arise once the cancer spreads, possibly causing pain in the hips, back, chest, or leading to erectile dysfunction, weight loss, fatigue, weakness, or loss of bladder control.

The U.S. Preventive Services Task Force recommends that men aged 55 to 69 have the choice to undergo PSA-based screening. Discussing potential benefits and risks with clinicians before opting for screening is advised, given the chance of false positives, overdiagnosis, or treatment complications. Non-invasive urine tests are also being researched for screening purposes.

Survival Rates and Factors

The ACS indicates a 99% five-year survival rate for localized prostate cancer. This rate remains for regional cases where the disease affects nearby tissues or lymph nodes. However, if cancer has metastasized to other body parts, the survival rate falls to 37%.

Survival rates depend on various factors such as patient age, health status, cancer progression, treatment response, and other individual nuances.